In addition, it has been confirmed that targeting Cav3.2 T-type channels can avoid hypersensitivity to pain associated with chemotherapy-induced peripheral neuropathy (CIPN) and diabetic neuropathy (Ghazisaeidi et al., 2023). Here, CACNA1H is linked to peripheral neuropathy.